Scarica l'app Stockscreener
2.68
0.00%
0.00
Dopo l'orario di chiusura:
2.59
-0.09
-3.36%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACRS Giù?
Forum
Previsione
Precedente Chiudi:
$2.68
Aprire:
$2.65
Volume 24 ore:
760.71K
Relative Volume:
0.61
Capitalizzazione di mercato:
$290.37M
Reddito:
$27.08M
Utile/perdita netta:
$-37.00M
Rapporto P/E:
-5.1538
EPS:
-0.52
Flusso di cassa netto:
$-18.46M
1 W Prestazione:
-10.96%
1M Prestazione:
-18.29%
6M Prestazione:
+84.83%
1 anno Prestazione:
+8.94%
Intervallo 1D:
$2.585
$2.69
Intervallo di 1 settimana:
$2.49
$3.04
Portata 52W:
$1.05
$3.475
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Nome
Aclaris Therapeutics Inc
Settore
Industria
Telefono
484-324-7933
Indirizzo
701 LEE ROAD, WAYNE, PA
Confronta ACRS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
2.68 | 290.37M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Piper Sandler | Overweight |
| 2025-05-28 | Iniziato | Wedbush | Outperform |
| 2025-03-18 | Ripresa | Cantor Fitzgerald | Overweight |
| 2024-12-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-11-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-19 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | Iniziato | Evercore ISI | Outperform |
| 2022-12-14 | Iniziato | Stifel | Buy |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2022-10-06 | Iniziato | BTIG Research | Buy |
| 2021-07-23 | Ripresa | Jefferies | Buy |
| 2021-06-15 | Iniziato | Piper Sandler | Overweight |
| 2021-04-21 | Iniziato | H.C. Wainwright | Buy |
| 2019-10-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Iniziato | SVB Leerink | Outperform |
| 2018-03-28 | Ripresa | Leerink Partners | Outperform |
| 2018-02-09 | Iniziato | Guggenheim | Buy |
| 2017-06-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Iniziato | Leerink Partners | Outperform |
| 2016-09-30 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-06-10 | Iniziato | Guggenheim | Buy |
| 2015-11-02 | Iniziato | Citigroup | Buy |
| 2015-11-02 | Iniziato | Jefferies | Buy |
Mostra tutto
Aclaris Therapeutics Inc Borsa (ACRS) Ultime notizie
What valuation multiples suggest for Aclaris Therapeutics Inc. stockWeekly Stock Analysis & Long-Term Growth Plans - ulpravda.ru
How Aclaris Therapeutics Inc. stock benefits from strong dollar2025 Breakouts & Breakdowns & AI Powered Trade Plan Recommendations - ulpravda.ru
Is Aclaris Therapeutics Inc. stock affected by interest rate hikesTrade Exit Report & Precise Swing Trade Alerts - ulpravda.ru
Will Aclaris Therapeutics Inc. stock benefit from green energy trendsMarket Performance Recap & Capital Protection Trade Alerts - ulpravda.ru
Market Recap: Can Aclaris Therapeutics Inc. (8AT) stock withstand sector downturnsJuly 2025 Pullbacks & Intraday High Probability Alerts - ulpravda.ru
Why analysts upgrade Aclaris Therapeutics Inc. stockMarket Sentiment Summary & Reliable Momentum Entry Alerts - ulpravda.ru
Aclaris joins Nasdaq biotech index, marking milestone for clinical-stage firm - MSN
Early Trial Data Puts Aclaris’ ATI-052 on Fast Track Toward Bigger Bets - MyChesCo
Why Aclaris Therapeutics Inc. stock could rally in 2025Long-Term Growth Stocks & Superior Growth Trading - ulpravda.ru
Jefferies reiterates Buy rating on Aclaris Therapeutics stock at $7 price target - Investing.com Canada
Aclaris Therapeutics Reports Positive Interim Phase 1a ATI-052 Data, Speeds Up Development Plans - MarketBeat
Aclaris Therapeutics Reports Positive Phase 1a Data For ATI-052 - Nasdaq
Aclaris advances ATI-052 after positive Phase 1a results - TipRanks
Aclaris Therapeutics Announces Positive Interim Results from Phase 1a Trial of ATI-052 - TradingView — Track All Markets
Aclaris reports positive results for anti-inflammatory drug ATI-052 By Investing.com - Investing.com Australia
ACRS: ATI-052 showed best-in-class potential in phase 1a, enabling rapid advancement to phase 1b trials - TradingView — Track All Markets
Aclaris Therapeutics Reports Positive Interim Results for ATI-052 Phase 1a Trials and Outlines Future Development Plans - Quiver Quantitative
New Aclaris antibody shows potential for 3‑month dosing in skin and asthma care - Stock Titan
What analysts say about Aclaris Therapeutics Inc 8AT stockStock Market Trends & Affordable Portfolio Trading - earlytimes.in
Hair Loss Treatment Market Booming with Rapid Growth Through 2032 | Viviscal, Cipla Inc., Aclaris Therapeutics, Inc. - openPR.com
Three Bridge Wealth Advisors LLC Takes Position in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Why Aclaris Therapeutics Inc. stock remains undervaluedMoving Average Strategies & Exceptional Profit Trading - bollywoodhelpline.com
Aclaris Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
What drives Aclaris Therapeutics Inc stock priceEarnings Forecast Updates & Big Profit Low Trading - earlytimes.in
Aclaris Joins Nasdaq Biotech Index, Marking Milestone for Clinical-Stage Firm - MyChesCo
Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to NASDAQ Biotechnology Index - marketscreener.com
Gains Report: Is Aclaris Therapeutics Inc stock a good choice for value investorsJuly 2025 Opening Moves & AI Forecast for Swing Trade Picks - moha.gov.vn
Is Aclaris Therapeutics Inc. (8AT) stock good for wealth creationWeekly Trade Recap & Low Drawdown Momentum Trade Ideas - Улправда
Will Aclaris Therapeutics Inc. stock deliver strong dividend growthJuly 2025 Breakouts & Risk Managed Investment Strategies - Улправда
Why Aclaris Therapeutics Inc. stock could see breakout soonJuly 2025 Sector Moves & Safe Capital Growth Tips - Улправда
Why Aclaris Therapeutics Inc. stock is rated strong buyJuly 2025 Gainers & Free Community Consensus Stock Picks - Улправда
How analysts rate Aclaris Therapeutics Inc. stock todayJuly 2025 Catalysts & Safe Capital Preservation Plans - Улправда
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) - The Manila Times
Layoff Watch: Why Aclaris Therapeutics Inc. stock could rally in 2025 - Улправда
Aclaris Therapeutics Begins Phase 1a/1b Trial for Investigational Bispecific Antibody ATI-052 - MSN
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index - Investing News Network
Aclaris Therapeutics Included in Nasdaq Biotechnology Index - marketscreener.com
Aclaris Therapeutics Added to Nasdaq Biotechnology Index Effective December 19, 2025 - Quiver Quantitative
Is Aclaris Therapeutics Inc. stock safe for conservative investorsJuly 2025 Weekly Recap & Weekly Top Stock Performers List - Улправда
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) 25% Share Price Surge Not Quite Adding Up - simplywall.st
Rally Mode: Is Aclaris Therapeutics Inc. (8AT) stock good for wealth creationTrade Risk Assessment & AI Forecasted Entry/Exit Points - Улправда
Aclaris Therapeutics Inc Azioni (ACRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):